TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02360124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silver diammine fluoride
Description: topical application of the SDF solution onto tooth root surfaces

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silver diammine fluoride
Description: topical application of the SDF solution onto tooth root surfaces

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water as placebo
Description: topical application of water as a placebo in the control arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saturated potassium iodide solution
Description: topical application of SDF solution followed by KI solution onto tooth root surfaces
Study: NCT00266461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daikenchuto Extract Granules (TU-100)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daikenchuto Extract Granules (TU-100)
Study: NCT01289990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Sitagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 low dose
Study: NCT03296488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
Study: NCT01106586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild
Description: Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV
Description: Atazanavir 300 mg capsule administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Ritonavir (RTV; /r) 100 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: FTC/TDF 200/300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stribild Placebo
Description: Placebo to match Stribild administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV Placebo
Description: Placebo to match ATV administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV Placebo
Description: Placebo to match RTV administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF Placebo
Description: Placebo to match FTC/TDF administered orally once daily
Study: NCT01211717

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched Chained Amino Acids
Description: Two doses of the Branched Chained Amino Acid supplement will be taken. The first dose will be taken 35 minutes before the intended exercise, and the other dose will be taken right after completing the exercise. The amount of the Branched Chained Amino Acid supplement administered to the subjects in the experimental group will vary from one person to the other but a total dose of 1 gram of BCAA per kilogram of lean body mass will be used. This dose will be divided in half and administered at the two specified occasions. The ratio of isoleucine, leucine, and valine will be 1:2.5:1 respectively

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose Placebo mix
Description: The control group will also take 2 doses, 1 before the exercise, and the other after completing the exercise. This dose will be divided in half and administered at the two specified occasions.
Study: NCT03894280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
Description: 2 inhalations in one study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SERETIDE DISKUS® 250/50 inhalation powder/GSK
Description: 2 inhalations in one study period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activated Charcoal suspension
Description: oral suspension before and after inhalation of study Investigational Products

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activated Charcoal suspension
Description: oral suspension before and after inhalation of study Investigational Products
Study: NCT01550822

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HEALS
Study: NCT01289990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching Sitagliptin
Study: NCT02117570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile vaccine
Description: 0.5 mL intramuscular injection on day 1, day 8, and day 30.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.
Study: NCT01351805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo pill
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo pill
Description: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Description: placebo
Study: NCT03424746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disodium EDTA
Description: Open-label study of TACT-formula, EDTA-based chelation therapy + commercially available TACT oral multi vitamins, delivering 40-50 infusions over 1 year.
Study: NCT01690650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen exposure (100% oxygen) for 5 minutes, then 25 minutes with room air. Repeated twice. Continuously monitoring of the cerebral oxygen saturation (NIRS).5 replacements of sensor for reproducibility.
Study: NCT00581945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to ACZ885 administered via intravenous infusion.
Study: NCT03555669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression Treatment
Description: The depression treatment program combines measurement-based antidepressant treatment with PST with clinical response appropriate to the level of depressive severity. Patients scoring 0-4 on the PHQ-9, indicating no depression, receive no treatment. Patients scoring 5-9 on the PHQ-9, indicating mild depressive symptoms that likely are not a full major depressive episode, are offered PST. Patients scoring 10 or above on the PHQ-9, indicating moderate-to-severe depressive symptoms, are first offered anti-depressants. For this group, PST will be an alternative or augmentation option for those who do not tolerate or respond to antidepressant treatment. All patients' depressive severity is monitored with the option of modifying their treatment plan if their symptoms worsen or do not improve.
Study: NCT01289990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching Sitagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: Sitagliptin once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 high dose
Study: NCT03534830

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: pre-operative MRI to be performed on all patients and then based on the imaging studies, the patient will be divided into the two comparative cohorts

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: pre-operative MRI to be performed on all patients and then based on the imaging studies, the patient will be divided into the two comparative cohorts
Study: NCT01226615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate (Condrosan®)
Description: 800mg (two capsules of 400mg each) taken once a day for four months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules taken once a day for four months.
Study: NCT01883531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Mannitol
Description: Active treatment is inhaled mannitol with a particle size of 3-4 microns

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: The PLacebo is non respirable mannitol due to the big size particle
Study: NCT03715660

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert bladder cancer monitor
Description: Xpert Bladder Cancer Monitor, is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer.The test utilizes a voided urine specimen and measures the levels of five targetmRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR). The Xpert Bladder Cancer Monitor is indicated as an aid to standard clinical evaluation in monitoring for bladder cancer recurrence in patients previously diagnosed with bladder cancer and should be used in conjunction with other clinical measures to assess disease recurrence.
Study: NCT01297634

Intervention type: DRUG
Group type: OTHER
Intervention: Botulinum Toxin Type-A (day 0)
Description: * Botulinum Toxin Type-A 1 unit. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 1 unit. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 1 unit. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.

Intervention type: DRUG
Group type: OTHER
Intervention: Botulinum Toxin Type-A (day 0)
Description: * Botulinum Toxin Type-A 2 Units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 2 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 2 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.

Intervention type: DRUG
Group type: OTHER
Intervention: Botulinum Toxin Type-A (day 0)
Description: Botulinum Toxin Type-A 3 units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 3 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 3 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Study: NCT03922815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue fentanyl
Description: a rescue dose of fentanyl 0,5 mcg per kilogram of body

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue fentanyl
Description: a rescue dose of fentanyl 0,5 mcg per kilogram of body

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue fentanyl
Description: a rescue dose of fentanyl 0,5 mcg per kilogram of body

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue propofol
Description: propofol in a single dose of 0,5 mg/kg of body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue propofol
Description: propofol in a single dose of 0,5 mg/kg of body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue propofol
Description: propofol in a single dose of 0,5 mg/kg of body weight
Study: NCT04270552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ismigen
Description: Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched tablets without any active substance.
Study: NCT04252326

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Doctors, Nurses and Dentists filled survey about adverse drug reractions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Doctors, Nurses and Dentists filled survey about adverse drug reractions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Doctors, Nurses and Dentists filled survey about adverse drug reractions
Study: NCT02557568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus carriage
Description: Staphylococcus aureus carriage is measured in the nose. Nasal samples were taken by the nursing staff of the ward using nylon flocked swab. Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus carriage
Description: Staphylococcus aureus carriage is measured in the nose. Nasal samples were taken by the nursing staff of the ward using nylon flocked swab. Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.
Study: NCT00306852

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt implant
Description: Patients will be randomized to receive a 350 mm\^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy with mitomycin C
Description: Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm\^2 Baerveldt glaucoma implant
Study: NCT01277406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4SC-201(Resminostat)
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: i.v. administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: i.v. administration
Study: NCT01033201

Intervention type: OTHER
Intervention: Confocal imaging
Description: At the time of the standard of care bronchoscopy, confocal images will be obtained from each consented patient.
Study: NCT02881970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous cord blood stem cell
Description: Injection of 5.107 / kg autologous mononuclear cells from umbilical cord blood
Study: NCT02812368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for clonidine)
Description: Placebo pill manufactured to mimic clonidine
Study: NCT04190966

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Behavioural therapy
Description: Integrated smoking cessation behavioural therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Pharmacotherapy
Description: Integrated smoking cessation pharmacotherapy including choice of combination nicotine replacement therapy, varenicline or electronic cigarettes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Web-based application
Description: Integrated smoking cessation web-based application
Study: NCT04221217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent
Description: Icosapent (MND-2119) capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent
Description: Icosapent (MND-2119) capsules.
Study: NCT03791515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitonin Gene-Related Peptide
Description: A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 1.5 µg/min CGRP over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 40 mL placebo (isotonic saline) over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion.
Study: NCT01956123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Delta (FE 999049)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Delta (FE 999049)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin Alfa (GONAL-F)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin Alfa (GONAL-F)
Study: NCT04946474

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xingnaojing injection + Shuxuetong oral liquid
Description: Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xingnaojing injection + Shuxuetong oral liquid
Description: Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).
Study: NCT02284373

Intervention type: OTHER
Group type: OTHER
Intervention: Flexitouch for 1 month in addition to routine wound care
Description: simultaneous wound care and pneumonic compression

Intervention type: OTHER
Group type: OTHER
Intervention: Routine wound care for venous ulcers and lymphedema
Description: wound care /dressings

Intervention type: DEVICE
Group type: OTHER
Intervention: Flexitouch pneumonic compression
Description: pneumonic compression only
Study: NCT01547572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The study group will get a video and leaflet on enhanced recovery
Description: The study group will get a video and leaflet
Study: NCT03857139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Participants will receive the transdermal nicotine patch (TNP) to use during the first 2 weeks post-quit. We chose the TNP because of the extensive empirical literature supporting its effectiveness and safety, ease of use, and relatively benign side effect profile. Anxiety and depressive symptoms predict poor smoking cessation outcomes among individuals receiving NRT , suggesting that emotional disturbance influences relapse even in the context of NRT.
Study: NCT03654807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Walking
Description: 70-80% HRmax

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Casual Speed Walking
Description: Self selected pace